Bortezomib-combination based therapy in relapsed-refractory myeloma patients

Haematologica Reports

Volumn 2, Issue 5, 2006, Pages 5-7

  Zappasodi, Patrizia ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ASCORBIC ACID; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE;

ADD ON THERAPY; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CARDIOVASCULAR SYMPTOM; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; HERPES ZOSTER; HUMAN; INFECTIOUS COMPLICATION; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROPATHY; NEUTROPENIA; PERIPHERAL NEUROPATHY; RECOMMENDED DRUG DOSE; THROMBOCYTOPENIA; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

EID: 46449094211     PISSN: 18249337     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003; 101:2377-80.
2. Ma MH, Yang HH, Parker K, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003; 9: 1136-1144.
3. Mitsiades N, Mitsiades CS, Poulaki V, et al. Apoptotic signalinginduced by immunomodulatory thalidomide analogs (IMiDs) in human multiple myeloma cells: therapeutic implications. Blood 2002; 99:4525-30.
4. Orlowski RZ, Voorhees PM, Garcia RA, et al. Phase I trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005; 105:3058-65.
5. Zangari M, Barlogie B, Burns MJ, et al. Velcade (V)-Thalidomide (T)-Dexamethasone (D) for advanced and refractory multiple myeloma (MM): long term follow up of phase I/II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106:2552.
6. Kropff M, Bisping G, Liebisch P, et al. Bortezomib in combination with high dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106:2549.
7. Terpos E, Anagnostopoulos A, Kastritis E, et al. The combination of Bortezomib, Melphalan, Dexamethasone and intermittent Thalidomide (VMDT) is an effective treatment for relapsed-refractory myeloma: results of a phase II clinical trial. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106:363.
8. Palumbo A, Ambrosini MT, Pregno P, et al. Velcade plus Melphalan, Prednisone and Thalidomide (V-MPT) for advanced multiple myeloma. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106:2553.
9. Popat R, Oakervee HE, Foot N, et al. A phase I/II study of Bortezomib and low dose intravenous Melphalan (BM) for relapsed multiple myeloma. Blood (ASH Annual Meeting Abstracts), Nov 2005;106:2555.
10. Richardson P, Schlossman R, Munshi N, et al. A phase 1 trial of Lenalidomide (REVLIMID) with Bortezomib (VELCADE) in relapsed and refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106: 365.
11. Berenson J, Matous J, Ferretti D, et al. A phase I/II trial evaluating the combination of Arsenic Trioxide, Bortezomib and Ascorbic Acid for patients with relapsed or refractory multiple myeloma. Blood (ASH Annual Meeting Abstracts), Nov 2005; 106:2565.